Anesthetic Management of Carcinoid Resection
Prophylactic octreotide administration is mandatory for all patients undergoing carcinoid tumor resection: administer 50 mcg/hour by continuous intravenous infusion starting 12 hours before surgery and continuing for at least 48 hours postoperatively, regardless of whether carcinoid syndrome is clinically present. 1
Preoperative Preparation
Octreotide Protocol
- Start octreotide infusion 50 mcg/hour IV 12 hours prior to surgery 1
- Continue throughout the perioperative period for minimum 48 hours postoperatively
- This applies to ALL patients with functioning carcinoid tumors, even those without overt carcinoid syndrome 1
- Have additional octreotide boluses (50-100 mcg IV) immediately available for intraoperative carcinoid crisis 2, 3
Cardiac Evaluation
Obtain cardiology consultation and echocardiogram preoperatively to assess for carcinoid heart disease, particularly in patients with:
- Clinical carcinoid syndrome
- 5-HIAA levels ≥300 mcmol (57 mg) over 24 hours
- ≥3 flushing episodes per day 4
Carcinoid heart disease occurs in 59% of patients with carcinoid syndrome and predominantly affects the tricuspid and pulmonary valves 4. Left-sided involvement is rare but has been reported 5.
Additional Preoperative Measures
- Correct fluid and electrolyte depletion from diarrhea 1
- For pancreatic NETs: add glucose infusion (insulinoma) or proton pump inhibitor (gastrinoma) 1
Intraoperative Management
Drug Avoidance - Critical
Strictly avoid medications that:
- Release histamine (morphine, atracurium, succinylcholine)
- Activate the sympathetic nervous system (ephedrine, dopamine in high doses)
- Trigger mediator release 1
Anesthetic Technique
- Use balanced anesthetic technique with careful hemodynamic monitoring 5
- Maintain stable hemodynamics throughout the procedure
- Avoid sudden changes in depth of anesthesia or surgical stimulation that may trigger mediator release
Managing Carcinoid Crisis
Carcinoid crisis presents as:
Treatment algorithm:
- Immediate octreotide bolus: 50-100 mcg IV 2, 3
- Increase octreotide infusion rate
- Phenylephrine infusion/boluses for hypotension (alpha-agonist preferred) 2
- May require alpha and beta blocking drugs for severe complications 1
- Avoid vasopressors that release catecholamines
Monitoring
- Invasive arterial blood pressure monitoring
- Central venous access for octreotide infusion and vasoactive medications
- Consider pulmonary artery catheter if significant cardiac involvement 5
High-Risk Periods
Carcinoid crisis is most likely during:
- Tumor manipulation/handling 3
- Hepatic artery embolization procedures 1
- Periods of surgical stress
- Massive blood loss (particularly during liver resection) 6
Maintain heightened vigilance and have octreotide boluses drawn up and ready during these critical periods.
Common Pitfalls
- Assuming absence of syndrome means no risk: Even patients without overt carcinoid syndrome can develop crisis during surgery 1
- Using standard vasopressors: Ephedrine and high-dose dopamine can trigger massive mediator release
- Inadequate octreotide coverage: Starting too late or discontinuing too early increases crisis risk
- Underestimating cardiac involvement: Carcinoid heart disease significantly increases perioperative mortality
Postoperative Care
- Continue octreotide infusion 50 mcg/hour for minimum 48 hours 1
- Monitor for delayed carcinoid crisis
- Maintain hemodynamic monitoring in ICU setting
- Transition to subcutaneous octreotide (150-250 mcg three times daily) before discontinuing infusion 4
The key to successful anesthetic management is prevention through prophylactic octreotide, meticulous drug selection avoiding histamine-releasing agents, and immediate recognition with aggressive treatment of carcinoid crisis using octreotide boluses and appropriate vasopressor support.